Interpretation of NCCN clinical practice guidelines for hepatocellular carcinoma,version 2.2023
10.16139/j.1007-9610.2024.02.02
- VernacularTitle:2023年第2版NCCN肝细胞癌临床实践指南解读
- Author:
Chunchao SHI
1
;
Kui WANG
Author Information
1. 海军军医大学第三附属医院肝外二科,上海 200433
- Keywords:
Hepatocellular carcinoma;
National Comprehensive Cancer Network(NCCN);
Guidelines;
Update
- From:
Journal of Surgery Concepts & Practice
2024;29(2):99-105
- CountryChina
- Language:Chinese
-
Abstract:
The National Comprehensive Cancer Network(NCCN),as the world′s leading non-profit consortium in the field of oncology,continues to update clinical practice guidelines for multiple malignancies annually and has become a benchmark for clinical practice guidelines in oncology worldwide.Currently,the NCCN clinical practice guidelines for hepatocellular carcinoma have been updated to version 2.2023,as compared with version 1.2023 of its main updates for the content of the discussion section.The NCCN guidelines for hepatobiliary cancers have been reorganized to separate guidelines for biliary tract cancers and hepatocellular carcinoma since version 1.2023.The main updates focus on tumor screening,diagnosis,surgery,adjuvant therapy,locoregional therapy,systemic therapy,and so on.The molecular testing was added for the first time.Therefore,the updates of version 1.2023 were highlighted again in the new version 2.2023.This article interpreted the new guidelines and focused on the aspects of updates.
